324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA

Documenti analoghi

• 811 | RAPID STEP‐UP DOSING SCHEDULE OF GLOFITAMAB IS SAFE AND EFFICACIOUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
  di: J. Yang, et al.
  Pubblicazione: (2025)
• 666 | OUTCOMES OF RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN AN ASIAN MULTIETHNIC COHORT
  di: N. Lim, et al.
  Pubblicazione: (2025)
• 182 | GENOMIC TESTING IN PATIENTS WITH LARGE CELL AND FOLLICULAR LYMPHOMA TREATED WITH T‐CELL ENGAGERS BI‐SPECIFIC ANTIBODIES AND CORRELATION WITH TREATMENT RESPONSE
  di: R. Tavarozzi, et al.
  Pubblicazione: (2025)
• 188 | INFLUENCE OF TP53 GENE ALTERATIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA TREATED WITH BISPECIFIC ANTIBODIES
  di: M. Bosch Schips, et al.
  Pubblicazione: (2025)
• 104 | A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)
  di: K. Patel, et al.
  Pubblicazione: (2025)